Photodynamic therapy: Oncologic horizons

Future Oncology

Volumn 10, Issue 1, 2014, Pages 123-142

  Allison, Ron R ^a  

^a 21ST CENTURY ONCOLOGY   (United States)

Author keywords

future photodynamic therapy; light source; oncology; photodynamic reaction; photodynamic therapy; photosensitizer; theranostic

Indexed keywords

AMINO LEVULONIC ACID; HEMATOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PRODRUG; PROTOPORPHYRIN; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG;

ASTROCYTOMA; BASAL CELL CARCINOMA; BILE DUCT CARCINOMA; BLADDER CANCER; BRAIN METASTASIS; BREAST CANCER; CANCER THERANOSTICS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLLAPSE; DOSIMETRY; DRUG CYTOTOXICITY; DRUG MECHANISM; EPENDYMOMA; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HEME SYNTHESIS; HUMAN; HYPOXIA; IMMUNE RESPONSE; LIGHT; LUNG CANCER; NANOTECHNOLOGY; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; UTERINE CERVIX CARCINOMA IN SITU; CENTRAL NERVOUS SYSTEM NEOPLASMS; DEVICES; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; LUNG NEOPLASMS; NEOPLASMS; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN NEOPLASMS;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS;

EID: 84903778429     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.176     Document Type: Review

References (162)

1. Agostinis P, Berg K, Cengel KA et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61(4), 250-281 (2011).
2. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy: a new concept in medical treatment. Braz. J. Med. Biol. Res. 33(8), 869-880 (2000).
3. Allison RR, Mota HC, Sibata CH. Clinical PD/PDT in North America: an historical review. Photodiagnosis Photodyn. Ther. 1(4), 263-277 (2004).
4. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res. 23(5A), 3591-3600 (2003).
5. Raab O. About the effect of fluorescent substances on infusoria. Z. Biol. 39, 524 (1900).
6. Jesionek A, von Tappiener H. For the treatment of Hautcarcinome with fluorescent materials. Münch Med. Wochschr. 47, 2042-2044 (1903).
7. Chargari C, Campana F, Pierga JY et al. Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat. Rev. Clin. Oncol. 7(11), 632-640 (2010).
8. Dougherty TJ. A brief history of clinical photodynamic therapy development at Roswell park cancer institute. J. Clin. Laser Med. Surg. 14(5), 219-221 (1996).
9. Gross SA, Wolfsen HC. The use of photodynamic therapy for diseases of the esophagus. J. Environ. Pathol. Toxicol. Oncol. 27(1), 5-21 (2008).
10. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem. Photobiol. Sci. 6(12), 1234-1245 (2007).
11. Dougherty TJ, Gomer CJ, Henderson BW et al. Photodynamic therapy. J. Natl Cancer Inst. 90(12), 889-905 (1998).
12. Allison RR, Downie GH, Cuenca R, Hu X, Childs CJ, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis Photodyn. Ther. 1(1), 27-42 (2004).
13. Allison RR, Sibata CH. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn. Ther. 7(2), 61-75 (2010). Good review of photosensitizers in PDT.
14. Bonnett R, Berenbaum MC. HPD - a study of its components and their properties. Adv. Exp. Med. Biol. 160, 241-250 (1983).
15. Hausman W. The photodynamic action of plant extracts containing chlorophyll. Biochem. Z. 12, 331-400 (1907).
16. Ben-Hur E, Rosenthal I. The phthalocyanines: a new class of mammalian cells photosensitizers with a potential for cancer phototherapy. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 47(2), 145-147 (1985).
17. Kudinova NV, Berezov TT. Photodynamic therapy of cancer: search for ideal photosensitizer. Biochem. (Moscow) Suppl. Ser. B Biomed. Chem. 4(1), 95-103 (2010).
18. Dougherty TJ. Photodynamic therapy. Photochem. Photobiol. 58(6), 895-900 (1993).
19. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B Biol. 14(4), 275-292 (1992).
20. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British photodermatology group. Br. J. Dermatol. 146(4), 552-567 (2002).
21. Cottrell WJ, Paquette AD, Keymel KR, Foster TH, Oseroff AR. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin. Cancer Res. 14(14), 4475-4483 (2008).
22. Zeitouni NC, Paquette AD, Housel JP et al. A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of nonmelanoma skin cancer. Lasers Surg. Med. 45(2), 89-94 (2013).
23. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem. Photobiol. 65(2), 235-251 (1997).
24. Togsverd-Bo K, Idorn LW, Philipsen PA, Wulf HC, Haedersdal M. Protoporphyrin IX formation and photobleaching in different layers of normal human skin: methyl- and hexylaminolevulinate and different light sources. Exp. Dermatol. 21(10), 745-750 (2012).
25. Bonnett R, White RD, Winfield UJ, Berenbaum MC. Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem. J. 261(1), 277-280 (1989).
26. Wyss P, Schwarz V, Dobler-Girdziunaite D et al. Photodynamic therapy of locoregional breast cancer recurrences using a chlorintype photosensitizer. Int. J. Cancer 93(5), 720-724 (2001).
27. Taber SW, Fingar VH, Coots CT, Wieman TJ. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. Clin. Cancer Res. 4(11), 2741-2746 (1998).
28. Tsutsumi M, Miki Y, Akimoto J et al. Photodynamic therapy with talaporfin sodium induces dose-dependent apoptotic cell death in human glioma cell lines. Photodiagnosis Photodyn. Ther. 10(2), 103-110 (2013).
29. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys. Med. Biol. 53(9), R61-R109 (2008).
30. Juzeniene A, Juzenas P, Ma LW, Iani V, Moan J. Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers Med. Sci. 19(3), 139-149 (2004).
31. Jacques SL. How tissue optics affect dosimetry of photodynamic therapy. J. Biomed. Opt. 15(5), 051608 (2010).
32. Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med. Sci. 17(3), 173-186 (2002).
33. Mang TS. Lasers and light sources for PDT: past, present and future. Photodiagnosis Photodyn. Ther. 1(1), 43-48 (2004).
34. Allison RR, Sibata CH. Photodynamic therapy: mechanism of action and role in the treatment of skin disease. G. Ital. Dermatol. Venereol. 145(4), 491-507 (2010).
35. Enk CD, Levi A. Low-irradiance red LED traffic lamps as light source in PDT for actinic keratoses. Photodermatol. Photoimmunol. Photomed. 28(6), 332-334 (2012).
36. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med. Sci. 24(2), 259-268 (2009).
37. Mang TS. Dosimetric concepts for PDT. Photodiagnosis Photodyn. Ther. 5(3), 217-223 (2008).
38. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 53(4), 549-553 (1991).
39. Niedre M, Patterson MS, Wilson BC. Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem. Photobiol. 75(4), 382-391 (2002).
40. Baker A, Kanofsky JR. Time-resolved studies of singlet-oxygen emission from L1210 leukemia cells labeled with 5-(N-hexadecanoyl)amino eosin. A comparison with a one-dimensional model of singlet-oxygen diffusion and quenching. Photochem. Photobiol. 57(4), 720-727 (1993).
41. Dysart JS, Singh G, Patterson MS. Calculation of singlet oxygen dose from photosensitizer fluorescence and photobleaching during mTHPC photodynamic therapy of MLL cells. Photochem. Photobiol. 81(1), 196-205 (2005).
42. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one - photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn. Ther. 1(4), 279-293 (2004).
43. Hamblin MR, Newman EL. On the mechanism of the tumour-localising effect in photodynamic therapy. J. Photochem. Photobiol. B Biol. 23(1), 3-8 (1994).
44. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part three photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn. Ther. 2(2), 91-106 (2005).
45. Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryot. Gene Expr. 16(4), 279-305 (2006).
46. Kwitniewski M, Juzeniene A, Glosnicka R, Moan J. Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy? Photochem. Photobiol. Sci. 7(9), 1011-1017 (2008).
47. Yoo JO, Ha KS. New insights into the mechanisms for photodynamic therapy-induced cancer cell death. Int. Rev. Cell Mol. Biol. 295, 139-174 (2012).
48. Casas A, Di Venosa G, Hasan T, Al B. Mechanisms of resistance to photodynamic therapy. Curr. Med. Chem. 18(16), 2486-2515 (2011).
49. Korbelik M, Zhang W, Merchant S. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol. Immunother. 60(10), 1431-1437 (2011).
50. Reiners JJ, Agostinis P, Berg K, Oleinick NL, Kessel D. Assessing autophagy in the context of photodynamic therapy. Autophagy 6(1), 7-18 (2010).
51. Moan J, Berg K, Kvam E et al. Intracellular localization of photosensitizers. Ciba Found. Symp. 146, 95-107 (1989).
52. Bhuvaneswari R, Gan YY, Soo KC, Olivo M. The effect of photodynamic therapy on tumor angiogenesis. Cell. Mol. Life Sci. 66(14), 2275-2283 (2009).
53. Gollnick SO, Evans SS, Baumann H et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br. J. Cancer 88(11), 1772-1779 (2003).
54. Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers 3(2), 2516-2539 (2011).
55. Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med. 38(5), 489-493 (2006).
56. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 62(6), 1604-1608 (2002).
57. Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 15(9), 1050-1071 (2010).
58. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 38(8), 2628-2635 (1978).
59. Zeitouni NC, Shieh S, Oseroff AR. Laser and photodynamic therapy in the management of cutaneous malignancies. Clin. Dermatol. 19(3), 328-338 (2001).
60. Allison RR, Sibata C, Downie GH, Cuenca RE. Photodynamic therapy of the intact breast. Photodiagnosis Photodyn. Ther. 3(3), 139-146 (2006).
61. Cuenca RE, Allison RR, Sibata C, Downie GH. Breast cancer with chest wall progression: treatment with photodynamic therapy. Ann. Surg. Oncol. 11(3), 322-327 (2004).
62. Morton CA. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol. Clin. 25(1), 81-87 (2007).
63. Szeimies RM, Radny P, Sebastian M et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled Phase III study. Br. J. Dermatol. 163(2), 386-394 (2010).
64. Morton C, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch. Dermatol. 142(6), 729-735 (2006).
65. Basset-Seguin N, Ibbotson SH, Emtestam L et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur. J. Dermatol. 18(5), 547-553 (2008).
66. Gold MH. Therapeutic and aesthetic uses of photodynamic therapy part five of a five-part series: ALA-PDT and MAL-PDT what makes them different. J. Clin. Aesthet. Dermatol. 2(2), 44-47 (2009).
67. Kostron H. Photodynamic diagnosis and therapy and the brain. Methods Mol. Biol. 635, 261-280 (2010).
68. Muller PJ, Wilson BC. Photodynamic therapy for recurrent supratentorial gliomas. Semin. Surg. Oncol. 11(5), 346-354 (1995).
69. Muller PJ, Wilson BC. Photodynamic therapy of brain tumors? A work in progress. Lasers Surg. Med. 38(5), 384-389 (2006).
70. Stylli SS, Kaye AH, MacGregor L, Howes M, Rajendra P. Photodynamic therapy of high grade glioma - long term survival. J. Clin. Neurosci. 12(4), 389-398 (2005).
71. Eljamel MS. Brain PDD and PDT unlocking the mystery of malignant gliomas. Photodiagnosis Photodyn. Ther. 1(4), 303-310 (2004).
72. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol. 7(5), 392-401 (2006).
73. Allison RR, Sibata C, Gay H. PDT for cancers of the head and neck. Photodiagnosis Photodyn. Ther. 6(1), 1-2 (2009).
74. Green B, Cobb AR, Hopper C. Photodynamic therapy in the management of lesions of the head and neck. Br. J. Oral Maxillofac. Surg. 51(4), 283-287 (2012).
75. D'Cruz AK, Robinson MH, Biel MA. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck 26(3), 232-240 (2004).
76. Hopper C, Kübler A, Lewis H, Tan IB, Putnam G; The Foscan 01 Study Group. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int. J. Cancer 111(1), 138-146 (2004).
77. Copper MP, Triesscheijn M, Tan IB, Ruevekamp MC, Stewart FA. Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx. Clin. Otolaryngol. 32(3), 185-189 (2007).
78. Jerjes W, Upile T, Akram S, Hopper C. The surgical palliation of advanced head and neck cancer using photodynamic therapy. Clin. Oncol. (R. Coll. Radiol.) 22(9), 785-791 (2010).
79. Biel M. Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg. Med. 38(5), 349-355 (2006).
80. Allison R, Moghissi K, Downie G, Dixon K. Photodynamic therapy (PDT) for lung cancer. Photodiagnosis Photodyn. Ther. 8(3), 231-239 (2011).
81. Moghissi K, Dixon K, Stringer M, Freeman T, Thorpe A, Brown S. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur. J. Cardiothorac. Surg. 15(1), 1-6 (1999).
82. Diaz-Jimenez JP, Martinez-Ballarin JE, Llunell A, Farrero E, Rodriguez A, Castro MJ. Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. Eur. Respir. J. 14(4), 800-805 (1999).
83. Vergnon JM, Huber RM, Moghissi K. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur. Respir. J. 28(1), 200-218 (2006).
84. Weinberg BD, Allison RR, Sibata C, Parent T, Downie G. Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer (NSCLC). Photodiagnosis Photodyn. Ther. 7(1), 50-58 (2010).
85. Moghissi K, Dixon K. O2 contribution of autofluorescence bronchoscopy (AFB) and photodynamic therapy (PDT) in the diagnosis and treatment of early central lung cancer (ECLC). Photodiagnosis Photodyn. Ther. 7(Suppl. 1), S5-S6 (2010).
86. Usuda J, Ichinose S, Ishizumi T et al. Management of multiple primary lung cancer in patients with centrally located early cancer lesions. J. Thorac. Oncol. 5(1), 62-68 (2010).
87. Usuda J, Ichinose S, Ishizumi T et al. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter. Clin. Cancer Res. 16(7), 2198-2204 (2010).
88. Moskal TL, Dougherty TJ, Urschel JD et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann. Thorac. Surg. 66(4), 1128-1133 (1998).
89. Pass HI. Photodynamic therapy in thoracic surgery. Ann. Thorac. Surg. 73(6), 2012-2013 (2002).
90. Friedberg JS, Cengel KA. Pleural malignancies. Semin. Radiat. Oncol. 20(3), 208-214 (2010).
91. Gross SA, Wolfsen HC. The role of photodynamic therapy in the esophagus. Gastrointest. Endosc. Clin. N. Am. 20(1), 35-53 (2010).
92. Yoon HY, Cheon YK, Choi HJ, Shim CS. Role of photodynamic therapy in the palliation of obstructing esophageal cancer. Korean J. Intern. Med. 27(3), 278-284 (2012).
93. Corti L, Skarlatos J, Boso C et al. Outcome of patients receiving photodynamic therapy for early esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 47(2), 419-424 (2000).
94. Overholt BF, Wang KK, Burdick JS et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's highgrade dysplasia. Gastrointest. Endosc. 66(3), 460-468 (2007).
95. Allison RR, Zervos E, Sibata CH. Cholangiocarcinoma: an emerging indication for photodynamic therapy. Photodiagnosis Photodyn. Ther. 6(2), 84-92 (2009).
96. Leggett CL, Gorospe EC, Murad MH, Montori VM, Baron TH, Wang KK. Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn. Ther. 9(3), 189-195 (2012).
97. Kiesslich T, Neureiter D, Wolkersdorfer GW, Plaetzer K, Berr F. Advances in photodynamic therapy for the treatment of hilar biliary tract cancer. Future Oncol. 6(12), 1925-1936 (2010).
98. Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125(5), 1355-1363 (2003).
99. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am. J. Gastroenterol. 100(11), 2426-2430 (2005).
100. Wolfsen HC. Uses of photodynamic therapy in premalignant and malignant lesions of the gastrointestinal tract beyond the esophagus. J. Clin. Gastroenterol. 39(8), 653-664 (2005).
101. Chen J, Keltner L, Christophersen J et al. New technology for deep light distribution in tissue for phototherapy. Cancer J. 8(2), 154-163 (2002).
102. Allison RR, Sheng C, Cuenca R, Bagnato VS, Austerlitz C, Sibata CH. Photodynamic therapy for anal cancer. Photodiagnosis Photodyn. Ther. 7(2), 115-119 (2010).
103. Allison RR, Cuenca R, Downie GH, Randall ME, Bagnato VS, Sibata CH. PD/PDT for gynecological disease: a clinical review. Photodiagnosis Photodyn. Ther. 2(1), 51-63 (2005).
104. Soergel P, Hillemanns P. Photodynamic therapy for intraepithelial neoplasia of the lower genital tract. Photodiagnosis Photodyn. Ther. 7(1), 10-14 (2010).
105. Soergel P, Loning M, Staboulidou I, Schippert C, Hillemanns P. Photodynamic diagnosis and therapy in gynecology. J. Environ. Pathol. Toxicol. Oncol. 27(4), 307-320 (2008).
106. Muroya T, Suehiro Y, Umayahara K et al. [Photodynamic therapy (PDT) for early cervical cancer.] Gan To Kagaku Ryoho 23(1), 47-56 (1996).
107. Ichimura H, Yamaguchi S, Kojima A et al. Eradication and reinfection of human papillomavirus after photodynamic therapy for cervical intraepithelial neoplasia. Int. J. Clin. Oncol. 8(5), 322-325 (2003).
108. Bodner K, Bodner-Adler B, Wierrani F et al. Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: a comparison of preliminary results. Anticancer Res. 23(2C), 1785-1788 (2003).
109. Lele SB, Piver MS, Mang TS, Dougherty TJ, Tomczak MJ. Photodynamic therapy in gynecologic malignancies. Gynecol. Oncol. 34(3), 350-352 (1989).
110. Fehr MK, Hornung R, Schwarz VA, Simeon R, Haller U, Wyss P. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol. Oncol. 80(1), 62-66 (2001).
111. Martin-Hirsch P, Kitchener HC, Hampson IN. Photodynamic therapy of lower genital tract neoplasia. Gynecol. Oncol. 84(1), 187-189 (2002).
112. Koren H, Alth G. Photodynamic therapy in gynaecologic cancer. J. Photochem. Photobiol. B Biol. 36(2), 189-191 (1996).
113. Cengel KA, Glatstein E, Hahn SM. Intraperitoneal photodynamic therapy. Cancer Treat. Res. 134, 493-514 (2007).
114. Hahn SM, Putt ME, Metz J et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin. Cancer Res. 12(18), 5464-5470 (2006).
115. Wilson JJ, Jones H, Burock M et al. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int. J. Oncol. 24(3), 711-717 (2004).
116. Nseyo UO, DeHaven J, Dougherty TJ et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J. Clin. Laser Med. Surg. 16(1), 61-68 (1998).
117. Prout GR, Lin CW, Benson R et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N. Engl. J. Med. 317(20), 1251-1255 (1987).
118. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a singlecenter study. Urology 61(2), 338-341 (2003).
119. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J. Urol. 175(4), 1201-1207 (2006).
120. Bader MJ, Stepp H, Beyer W et al. Photodynamic therapy of bladder cancer - a Phase I study using hexaminolevulinate (HAL). Urol. Oncol. 31(7), 1178-1183 (2012).
121. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence owing to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int. 108(8 Pt 2), E297-E303 (2011).
122. Otto W, Burger M, Fritsche HM, Rossler W, Wieland WF, Denzinger S. The enlightenment of bladder cancer treatment: origin and progress of photodynamic diagnosis. Future Oncol. 7(9), 1057-1066 (2011).
123. Nathan TR, Whitelaw DE, Chang SC et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a Phase I study. J. Urol. 168(4Pt 1), 1427-1432 (2002).
124. Du KL, Mick R, Busch TM et al. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg. Med. 38(5), 427-434 (2006).
125. Trachtenberg J, Bogaards A, Weersink RA et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J. Urol. 178(5), 1974-1979 (2007).
126. Moore CM, Nathan TR, Lees WR et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg. Med. 38(5), 356-363 (2006).
127. Svaasand LO. Optical dosimetry for direct and interstitial photoradiation therapy of malignant tumors. Prog. Clin. Biol. Res. 170, 91-114 (1984).
128. Liu B, Farrell TJ, Patterson MS. Comparison of noninvasive photodynamic therapy dosimetry methods using a dynamic model of ALA-PDT of human skin. Phys. Med. Biol. 57(3), 825-841 (2012).
129. Saager RB, Cuccia DJ, Saggese S, Kelly KM, Durkin AJ. A light emitting diode (LED) based spatial frequency domain imaging system for optimization of photodynamic therapy of nonmelanoma skin cancer: quantitative reflectance imaging. Lasers Surg. Med. 45(4), 207-215 (2013).
130. Honda N, Ishii K, Terada T, Nanjo T, Awazu K. Determination of the tumor tissue optical properties during and after photodynamic therapy using inverse Monte Carlo method and double integrating sphere between 350 and 1000 nm. J. Biomed. Opt. 16(5), 058003 (2011).
131. Valentine RM, Brown CT, Moseley H, Ibbotson S, Wood K. Monte Carlo modeling of in vivo protoporphyrin IX fluorescence and singlet oxygen production during photodynamic therapy for patients presenting with superficial basal cell carcinomas. J. Biomed. Opt. 16(4), 048002 (2011).
132. Allison RR. The electromagnetic spectrum: current and future applications in oncology. Future Oncol. 9(5), 657-667 (2013).
133. Allison RR, Sibata CH. Photofrin photodynamic therapy: 2.0 mg/kg or not 2.0 mg/kg that is the question. Photodiagnosis Photodyn. Ther. 5(2), 112-119 (2008).
134. Allison RR, Moghissi K. Photodynamic therapy (PDT): PDT mechanisms. Clin. Endosc. 46(1), 24-29 (2013).
135. Zhu TC. Dosimetry in pleural photodynamic therapy. J. Natl Compr. Canc. Netw. 10(Suppl. 2), S60-S64 (2012).
136. Dimofte A, Finlay JC, Liang X, Zhu TC. Determination of optical properties in heterogeneous turbid media using a cylindrical diffusing fiber. Phys. Med. Biol. 57(19), 6025-6046 (2012).
137. Valentine RM, Ibbotson SH, Wood K, Brown CT, Moseley H. Modelling fluorescence in clinical photodynamic therapy. Photochem. Photobiol. Sci. 12(1), 203-213 (2013).
138. Jarvi MT, Patterson MS, Wilson BC. Insights into photodynamic therapy dosimetry: simultaneous singlet oxygen luminescence and photosensitizer photobleaching measurements. Biophys. J. 102(3), 661-671 (2012).
139. Ebert B, Grosenick D. Optical imaging of breast tumors and of gastrointestinal cancer by laser-induced fluorescence. Recent Results Cancer Res. 187, 331-350 (2013).
140. Eljamel MS. Fluorescence image-guided surgery of brain tumors: explained step-by-step. Photodiagnosis Photodyn. Ther. 5(4), 260-263 (2008).
141. Allison RR, Sibata CH. Photodiagnosis for cutaneous malignancy: a brief clinical and technical review. Photodiagnosis Photodyn. Ther. 5(4), 247-250 (2008).
142. Moghissi K, Dixon K, Stringer MR. Current indications and future perspective of fluorescence bronchoscopy: a review study. Photodiagnosis Photodyn. Ther. 5(4), 238-246 (2008).
143. Rosenkranz AA, Jans DA, Sobolev AS. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol. Cell Biol. 78(4), 452-464 (2000).
144. Allison RR, Mota HC, Bagnato VS, Sibata CH. Bio-nanotechnology and photodynamic therapy - state of the art review. Photodiagnosis Photodyn. Ther. 5(1), 19-28 (2008).
145. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv. Drug Deliv. Rev. 60(15), 1627-1637 (2008).
146. Hsu CY, Chen CW, Yu HP, Lin YF, Lai PS. Bioluminescence resonance energy transfer using luciferase-immobilized quantum dots for self-illuminated photodynamic therapy. Biomaterials 34(4), 1204-1212 (2013).
147. Zuluaga MF, Mailhos C, Robinson G, Shima DT, Gurny R, Lange N. Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 48(4), 1767-1772 (2007).
148. Cinteza LO, Ohulchanskyy TY, Sahoo Y, Bergey EJ, Pandey RK, Prasad PN. Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy. Mol. Pharm. 3(4), 415-423 (2006).
149. Koo YE, Fan W, Hah H et al. Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy. Appl. Opt. 46(10), 1924-1930 (2007).
150. Josefsen LB, Boyle RW. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2(9), 916-966 (2012).
151. Allison RR, Mota HC, Sibata CH. Clinical PD/PDT in North America: an historical review. Photodiagnosis Photodyn. Ther. 1(4), 263-277 (2004).
152. Allison RR. Future PDT. Photodiagnosis Photodyn. Ther. 6(3-4), 231-234 (2009).
153. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol. 59(7), 733-739 (2000).
154. Mehta MP, Shapiro WR, Glantz MJ et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J. Clin. Oncol. 20(16), 3445-3453 (2002).
155. Berg K, Selbo PK, Prasmickaite L et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 59(6), 1180-1183 (1999).
156. Weyergang A, Selbo PK, Berstad ME, Bostad M, Berg K. Photochemical internalization of tumor-targeted protein toxins. Lasers Surg. Med. 43(7), 721-733 (2011).
157. Allison RR, Bagnato VS, Sibata CH. Future of oncologic photodynamic therapy. Future Oncol. 6(6), 929-940 (2010).
158. Mathews MS, Angell-Petersen E, Sanchez R et al. The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids. Lasers Surg. Med. 41(8), 578-584 (2009).
159. Wiegell SR, Fabricius S, Heydenreich J et al. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br. J. Dermatol. 168(1), 186-191 (2013).
160. Allison RR, Sibata CH. Photodiagnosis for cutaneous malignancy: a brief clinical and technical review. Photodiagnosis Photodyn. Ther. 5(4), 247-250 (2008).
161. Daily Med. Photofrin (porfimer sodium) injection, powder, for solution [Axcan Scandipharm Inc.]. http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=f5fdda24-da7d-4e61-936e-9d1a55056b82
162. ClinicalTrials.gov. www.clinicaltrials.gov